孟鲁司特钠联合布地奈德治疗支气管哮喘的价值分析及评估

Value Analysis and Evaluation of Montelukast Sodium Combined with Budesonide in the Treatment of Bronchial Asthma

目的探讨孟鲁司特钠联合布地奈德治疗支气管哮喘的价值。方法根据随机数字表法将方便选取2016年6月—2018年2月该院诊治的90例支气管哮喘患者分成不同组。对照组给予布地奈德治疗,观察组则给予布地奈德联合孟鲁司特钠治疗。比较两组支气管哮喘治疗效果;咳嗽消失时间、哮喘控制时间、伴发症状消失时间;治疗前后患者肺功能指标和血清免疫学指标;治疗不良反应率。结果观察组支气管哮喘治疗效果44例(97.78%)高于对照组31例(68.89%),差异有统计学意义(χ~2=13.520 0,P<0.05);观察组咳嗽消失时间、哮喘控制时间、伴发症状消失时间(4.11±1.42)d、(3.24±1.10)d、(3.20±0.24)d优于对照组(6.42±2.25)d、(4.77±2.13)d、(4.81±1.51)d,(t=8.292、8.201、9.124,P<0.05);治疗后观察组肺功能指标和血清免疫学指标优于对照组(P<0.05)。观察组治疗不良反应率3例(6.67%)和对照组2例(4.44%),差异无统计学意义(χ~2=0.211 8,P>0.05)。结论布地奈德联合孟鲁司特钠治疗支气管哮喘的应用效果确切,可有效改善肺功能指标和血清免疫学指标,加速症状消失,缩短疗程,且无严重不良反应,安全有效,值得推广应用。

Objective To investigate the value of montelukast sodium combined with budesonide in the treatment of bronchial asthma. Methods According to the random number table method, 90 patients with bronchial asthma from June 2016 to February 2018 were divided into different groups. The control group was treated with budesonide, and the observation group was given budesonide combined with montelukast sodium. The therapeutic effects of bronchial asthma were compared between the two groups; the time of cough disappearance, the time of asthma control, and the disappearance time of accompanying symptoms; the lung function index and serum immunological index before and after treatment; the side effect rate were observed. Results The therapeutic effect of bronchial asthma in the observation group was 44 cases（97.78%） higher than that in the control group 31 cases（68.89%）, the difference was statistically signficant（X^2=13.5200, P〈0.05）. The disappearance time of cough in the observation group, the time of asthma control, and the disappearance time of accompanying symptoms were （4.11±1.42）d, （3.24±1.10）d, （3.20±0.24）d were better than the control group （6.42±2.25）d, （4.77±2.13）d, （4.81±1.51）d,the difference was statistically signficant （t=8.292, 8.201, 9.124, P〈0.05）; the lung function index and serum immunological index of the observation group after treatment, better than the control group （P〈0.05）. There was no significant difference between the observation group＇s treatment side effect rate 3 cases （6.67） and the control group 2 cases （4.44%）,the difference was statistically signficant （X^2=0.2118, P〉0.05）. Conclusion The application of budesonide combined with montelukast sodium in the treatment of bronchial asthma is effective, can effectively improve the lung function index and serum immunological indicators, accelerate the disappearance of symptoms, shorten the course of treatment, without serious adverse reactions, safe and effective, worthy of popularization and application.